Table 1 Baseline demographics and clinical characteristics of patients infected by SARS-CoV-2 per year of inclusion and differences over the years.

From: Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Characteristics

Year

Total

P-value

 

2020

2021

2022

 

Δ 2020–2021 versus 2022#

N = 39

N = 35

N = 106

N = 180

Age, median age in years (min-max) at COVID-19

58.5 (5.2–72.8)

55.2 (17.6–72.6)

61.3 (20.2–78.4)

58.9 (5.2–78.4)

 

56.2 (5.2–72.8)

61.3 (20.2–78.4)

0.01**

Female sex, N (%)

17 (43.6)

17 (48.6)

34 (32.1)

68 (37.8)

0.06

CAR T-cell therapy indication, N (%)

0.7

 Acute leukemia

5 (12.8)

5 (14.3)

10 (9.4)

20 (11.1)

 

 B-NHL

32 (82.1)

27 (77.1)

89 (84.0)

148 (82.2)

 

 Multiple myeloma

2 (5.1)

3 (8.6)

7 (6.6)

12 (6.7)

 

Disease status at time of COVID-19 diagnosis, N (%)

0.09

 Relapse/Progression

8 (20.5)

7 (20)

13 (12.3)

28 (15.5)

 

 Partial response

4 (10.3)

5 (14.3)

9 (8.5)

18 (10)

 

 Complete response

27 (69.2)

22 (62.9)

81 (76.4)

130 (72.2)

 

 Unknown

0 (0.0)

1 (2.9)

3 (2.8)

4 (2.2)

 

Metabolic comorbidity*, N (%)

11 (28.2)

10 (28.6)

36 (34.0)

57 (31.7)

0.3

 Unknown

0 (0.0)

5 (14.3)

10 (9.4)

15 (8.3)

 

Lansky/Karnofsky-score < 70 at COVID-19 diagnosis, N (%)

9 (23.1)

3 (8.6)

8 (7.5)

20 (11.1)

0.1

 Unknown

0 (0.0)

1 (2.9)

15 (14.2)

16 (8.9)

 

Median time from CAR-T to COVID-19 diagnosis, months (min days-max months)

7.7 (1–17.5)

7.4 (6–37.1)

6.4 (5–42.5)

7.2 (1–42.5)

0.6

Symptoms at time of COVID-19 diagnosis, N (%)

 Asymptomatic

5 (12.8)

3 (9.1)

14 (13.5)

22 (12.2)

0.6

 Fever

26 (66.7)

19 (54.3)

46 (43.4)

91 (50.6)

 

45 (60.8)

46 (43.4)

 

0.02**

 Upper respiratory symptoms

17 (43.6)

13 (37.1)

64 (60.4)

94 (52.2)

 

30 (40.5)

64 (60.4)

 

0.02**

 Lower Respiratory symptoms

15 (38.5)

13 (37.1)

23 (21.7)

51 (28.3)

 

28 (37.8)

23 (21.7)

 

0.01**

Oxygen support, N (%)

18 (46.2)

14 (40.0)

27 (25.5)

59 (32.8)

 

32 (43.2)

27 (25.5)

 

0.01**

 Missing

0 (0.0)

3 (8.6)

3 (2.8)

6 (3.3)

 

 Invasive mechanical ventilation

8/18 (44.4)

7/14 (50.0)

3/27 (11.1)

18/59 (30.5)

 

Hospital admission, N (%)

32 (82.1)

23 (65.7)

46 (43.4)

101 (56.1)

 

55 (74.3)

46 (43.4)

 

<0.0001**

 Missing

0 (0.0)

2 (5.7)

0 (0.0)

2 (1.1)

 

Median hospital admission duration, days (min-max)

23.5 (1–93)

18 (2–82)

11 (1–280)

17.5 (1–280)

 

21(1–93)

11 (1–280)

  

ICU admission, N (%)

15 (38.5)

10 (28.6)

6 (5.7)

31 (17.2)

 

25 (33.8)

6 (5.7)

 

<0.0001**

 Missing

1 (2.6)

1 (2.9)

0 (0.0)

2 (1.1)

 

Median ICU admission duration, days (min-max)

20.0 (2–68)

17.5 (7–38)

7.5 (3–57)

13.5 (2–68)

 

19 (2–68)

7.5 (3–57)

  
  1. B-NHL B-cell Non-Hodgkin Lymphoma.
  2. *Metabolic comorbidities include obesity, hypertension, diabetes, hypercholesterolemia, smoking and cardiovascular disease ** significant. # The P values given in this table are for the comparison of the years 2020 and 2021 combined with the year 2022 ** significant P value.
Back to article page